A Multi-centre, Prospective, Open Label, Single-arm, Non-interventional Post-marketing Study to Investigate the Long-term Safety and Clinical Parameters of Sogroya Treatment in Children With Short Stature Due to Growth Hormone Deficiency Where Epiphysial Discs Are Not Closed Under Normal Clinical Practice Conditions in Japan Special Use-results Surveillance on Long Term Use of Sogroya in Children With Short Stature Due to Growth Hormone Deficiency (GHD) Where Epiphysial Discs Are Not Closed
Latest Information Update: 23 Aug 2024
At a glance
- Drugs Somapacitan (Primary)
- Indications Somatotropin deficiency
- Focus Adverse reactions
- Sponsors Novo Nordisk
Most Recent Events
- 03 Nov 2023 New trial record